Rapport Therapeutics, Inc. - Officer Stock Sale Transaction

On April 10, 13, and 14, 2026, Yeleswaram Krishnaswamy, Chief Development Officer of Rapport Therapeutics, Inc., sold a total of 19,865 shares of the company's Common Stock. These transactions were executed under a Rule 10b5-1 trading plan. The sales occurred at a weighted average price of approximately $35.00 per share, with individual transactions ranging from $34.90 to $35.37. Following these sales, Mr. Krishnaswamy directly owns 266,651 shares of Rapport Therapeutics, Inc. stock. The reporting person has undertaken to provide further details on specific prices upon request.